Xilio Therapeutics, Inc.XLONASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank32
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

Percentile
P32
Within normal range
vs 2Y Ago
-0.8x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
PeriodValue
Q3 2025-17.59%
Q2 2025-151.38%
Q1 2025304.45%
Q4 2024-3.52%
Q3 2024-168.64%
Q2 2024289.79%
Q1 202421.78%
Q4 2023-0.43%
Q3 202320.85%
Q2 202333.56%
Q1 2023-35.70%
Q4 20227.46%
Q3 2022-15.49%
Q2 202216.89%
Q1 2022-20.23%
Q4 202115.81%
Q3 2021-1.26%
Q2 202110.17%
Q1 2021-78.76%
Q4 2020-16.11%
Q3 2020-126245.32%
Q2 2020-53.31%
Q1 20200.00%